NEWS SOURCE: Epeius Biotechnologies Corporation
SAN FRANCISCO, Calif., Oct. 20 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco. Participating companies that are poised for leadership status in areas of therapeutic innovation are chosen through a competitive screening process, with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry.
The selection of Epeius Biotechnologies as an investment opportunity was based on the accomplishment of significant clinical development milestones with its lead oncology product, Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors by the Philippine FDA, and has recently received both Orphan Drug priorities and Fast Track designation by the U.S. FDA.
Epeius Biotechnologies is among a select group of companies which are recognized as those that are creating real value through development-stage programs with near-term clinical catalysts. According to the top-tier investor forum advisory committee, “These are the companies that will help drive the investment and deal making in the life sciences sector and global innovation in healthcare.”
This prestigious forum provides an opportunity for senior management of Epeius Biotechnologies to showcase the remarkable clinical development of Rexin-G®, as stand-alone therapy for otherwise intractable metastatic cancers, and to partner with savvy investors that are capable of expediting the development of Rexin-G in the larger global market.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.
To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at www.epeiusbiotech.com.
News issued by: Epeius Biotechnologies Corporation
Original Image: https://www.send2press.com/wire/images/09-1012-EpeiusBio_72dpi.jpg
# # #
Original Story ID: (5408) :: 2009-10-1020-003
Original Keywords: 8th Annual BIO Investor Forum, Epeius Biotechnologies, Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors, Frederick L. Hall, Dr. Erlinda M. Gordon, therapeutic innovation, investing and banking in the life sciences industry Epeius Biotechnologies Corporation
NEWS SOURCE: Epeius Biotechnologies Corporation | Published: 2009-10-20 13:17:36
IMPORTANT NOTICE FOR ARCHIVAL CONTENT ABOVE: The above archival press release content was issued on behalf of the noted "news source" who provided the content (text and image[s]) and is solely responsible for its accuracy. Links may not work if very old; use such with caution. Send2Press does not represent the "news source" in any capacity. For questions about this content contact the company/person mentioned directly. To report fraud or illegal material, or DMCA complaints, please contact Send2Press via our main site (any such complaints must be made in writing, not by phone).
